Gene therapy is becoming a promising solution for retinal degenerative diseases, as the retina offers an excellent setting for studying and treating eye conditions. Importantly, it was the first ti...
Lilly Strengthens IBD Treatment Portfolio with Morphic Acquisition Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for serious chronic diseases. Lilly will initiate a tender offer to acqu...
Find More
Alcon's Newest Technological Marvels, Unity VCS, and Unity CS, Achieved 510(k) Clearance From the U.S. FDA, Paving the Way for New Advancements On June 24, 2024, Alcon, the foremost name in eye care with a mission to help people see brilliantly, revealed that the U.S. Food and Drug Administration (FDA) had...
Find More
Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...
Find More
Stryker Released LIFEPAK 35 Monitor/Defibrillator On June 04, 2024, Stryker, a global leader in medical technologies, announced the launch of the LIFEPAK 35 monitor/defibrillator. This latest addition to their monitor/defibrillator lineup features advanced technology and is designed on an intuitive, modern...
Find More
Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular is...
Find More
Glaucoma, often dubbed as the “silent thief of sight,” poses a significant challenge in the domain of ophthalmology. Glaucoma treatment has made significant strides, yet several unmet needs persist, posing challenges to effective management and vision preservation. By prioritizing early detection, embracing persona...
Find More
Carl Zeiss Meditec AG Completed Acquisition of Dutch Ophthalmic Research Center (D.O.R.C); Companies Unite to Shape Ophthalmology Market On April 04, 2024, Carl Zeiss Meditec AG announced that it acquired D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. T...
Find More
Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...
Find More
TELA Bio Launched FDA-approved Hernia Mesh Fixation Devices On March 21, 2024, TELA Bio, Inc., a medical technology firm, launched its FDA-approved LIQUIFIX devices for hernia repairs in the United States. The LIQUIFIX FIX8™ and LIQUIFIX Precision™ are specifically engineered for laparoscopic and open femo...
Find More
Osteosarcoma is a kind of bone cancer that originates from the cells that form bones. It is often fo.....
Find More
Alzheimer's disease is an irreversible, progressive disorder of the brain that progressively destroy.....
Find More
Today, Artificial Intelligence has been used effectively in data processing, drug discovery, aiding .....
Find More
Value-Based Healthcare is that healthcare model or a process where the providers, including hospital.....
Find More
Lyme disease is a vector-borne infectious disease that spreads primarily by the bite of a tick (also.....
Find More
Past decades have witnessed a shift in the focus of researchers and pharma companies towards tailori.....
Find More-Agonist.png "Toll-like Receptors Agonist")
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!
